JNC V versus clinical reality: An american practitioner's perspective

Cardiovascular Reviews and Reports

Volumn 17, Issue 3, 1996, Pages 31-36

  Gutkin, Michael ^a,b,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c FACC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE THERAPY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY RISK; DRUG CHOICE; DRUG INDICATION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0029932747     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
2. Julius S, Jamerson K, Mejia A, et al. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh blood pressure study. JAMA. 1990;264:354-358
3. Selby JV, Newman B, Quiroga J, et al. Concordance for dyslipidemic hypertension in male twins. JAMA. 1991;265:1079-1084.
4. Sasson Z, Rasooly Y, Bhesania T, et al. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation. 1993;88(pt. 1):1431-1436.
5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation. 1972;45:991-1004.
6. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial: The Oslo study. Am J Med. 1980;69:725-732.
7. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet. 1980;1:1261-1267.
8. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Med J Aust. 1981;2:398-402.
9. Amery A, Brixko P, Clement D, et al. Mortality and morbidityresults from the European working party on high blood pressure in the elderly trial. Lancet. 1985;1:1349-1354.
10. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J. 1985;291:97-104.
11. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J. 1986;293:1145.
12. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
13. Dahlöf B, Lindholm L, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
14. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults. Principal results. Br Med J. 1992;304:405-412.
15. Hypertension Detection and Follow-up Program Cooperative Group. Reduction in mortality of persons with high blood pressure, including mild hypertension: Five-year findings of the hypertension detection and follow-up program. JAMA. 1979;242:2562-2571.
16. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: Mortality by race, sex and age. JAMA. 242:2572-2577.
17. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:2562-2571.
18. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in "mild" hypertension. N Engl J Med. 1982;307:967-980.
19. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. JAMA. 1982;248:1465-1477.
20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity: Results in patients with diastolic blood pressure averaging 115 through 120 mm Hg. JAMA 1967;202:1028.
21. The IPPPSH Collaborative Group. The Internal Prospective Primary Prevention Study in Hypertension (IPPPSH): Objectives and methods. Eur J Clin Pharmocol. 1984;27:379-391.
22. The Management Committee of the Australian National Blood Pressure Study. Prognostic factors in the treatment of mild hypertension. Circulation. 1984;69:668-676.
23. Williams RR, Hopkins PN, Hunt SC, et al. Familial dyslipidaemic hypertension and other multiple metabolic syndromes. Ann Med. 1992;24:469-475.
24. Williams RR, Hopkins PN, Hunt SC, et al. Familial dyslipidaemic hypertension: Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:3579-3586.
25. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. JAMA. 1984;251:351-364.
26. Streeten DHP, Auchincloss JH Jr, Anderson GH Jr, et al. Orthostatic hypertension. Pathogenetic studies. Hypertension. 1985;7:196-203.
27. Melby JC. Diagnosis of hyperaldosteronism. Endocrinol Metab Clin North Am. 1991;20:247-255.
28. Dahlöff B. Regression of left ventricular hypertrophy: Are there differences between antihypertensive agents? Cardiology. 1992;81:307-315.
29. Moser M. Relative efficacy of, and some adverse reactions to, different antihypertensive regimens. Am J Cardiol. 1989;63:2B-7B.
30. Criqui MH, Heiss G, Cohn R, et al. Plasma triglycride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
31. Cambien F, Jacqueson A, RichardJL, et al. Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? Am J Epidemiol. 1986;124:624-632.
32. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
33. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85:37-45.
34. Burchfiel CM, Laws A, Benfante R, et al. Combined effects of HDL cholesterol, triglycride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation. 1995;92:1430-1436.
35. Fuller JH, Shipley MJ, Rose G, et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J. 1983;287:867-870.
36. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study: Final results. JAMA. 1993;270:713-724.
37. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
38. Surveillance for selected tobacco-use behaviors - United States, 1900-1994. MMWR. 1994;43.
39. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. JAMA. 1994;272:238-239.